D&D Collectibles

D&D Pharmatech is a clinical-stage biopharmaceutical company based in South Korea that focuses on developing innovative therapies for metabolic and neurodegenerative diseases. The company leverages several proprietary technology platforms, including the ORALIA platform for oral peptide delivery and the P-SENS platform for neuro-imaging. Its clinical pipeline is led by NLY01, a long-acting GLP-1 receptor agonist for Parkinson's disease, and DD01, a dual GLP-1/glucagon receptor agonist for MASH. D&D Pharmatech operates through a network of US-based subsidiaries such as Neuraly and Theraly, which were founded on research from Johns Hopkins University. In 2024, the company achieved a significant milestone by going public on the KOSDAQ and entering a major licensing agreement with Metsera for its oral obesity programs.